Welcome to SigmaDrugs!

Our biotech company is dedicated to find novel therapeutic targets and develop new pharmaceutical compounds for the treatment of fibroproliferative diseases of various organs.  

Nearly the half of all-death worldwide is attributed to fibroproliferative diseases (eg. pulmonary fibrosis, chronic kidney disease, etc). Fibrosis alters tissue architecture and leads to organ dysfunction.  Although the fibrotic process is universal and symptoms are similar regardless of the affected organ, currently there is no specific therapy that can effectively inhibit the progression. Thus, the demand for antifibrotic drugs is enormous and would have a huge impact on the lives of millions.